Thumbnail Image
Item

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma

Amodio, N
; 
Leotta, M
; 
Bellizzi, D
; 
DI Martino, MT
; 
D'Aquila, P
; 
Lionetti, M
; 
Fabiani, F
; 
Leone, E
; 
Gullà, AM
; 
Passarino, G
... show 6 more
Citations
Altmetric:
Genre
Journal Article
Date
2012-01-01
Advisor
Committee member
Group
Department
Subject
miR-29b
 microRNA
 multiple myeloma
 DNA methyltransferases
 DNMT
Permanent link to this record
http://hdl.handle.net/20.500.12613/5485
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.pdf
Adobe PDF, 2.45 MB
Research Projects
Organizational Units
Journal Issue
DOI
10.18632/oncotarget.675
Abstract
Aberrant DNA methylation plays a relevant role in multiple myeloma (MM) pathogenesis. MicroRNAs (miRNAs) are a class of small non-coding RNAs that recently emerged as master regulator of gene expression by targeting protein-coding mRNAs. However, miRNAs involvement in the regulation of the epigenetic machinery and their potential use as therapeutics in MM remain to be investigated. Here, we provide evidence that the expression of de novo DNA methyltransferases (DNMTs) is deregulated in MM cells.Moreover, we show that miR-29b targets DNMT3A and DNMT3B mRNAs and reduces global DNA methylation in MM cells. In vitro transfection of MM cells with synthetic miR-29b mimics significantly impairs cell cycle progression and also potentiates the growth-inhibitory effects induced by the demethylating agent 5-azacitidine. Most importantly, in vivo intratumor or systemic delivery of synthetic miR-29b mimics, in two clinically relevant murine models of human MM, including the SCID-synth-hu system, induces significant anti-tumor effects. All together, our findings demonstrate that aberrant DNMTs expressionis efficiently modulated by tumor suppressive synthetic miR-29b mimics, indicating that methyloma modulation is a novel matter of investigation in miRNA-based therapy of MM. copy; Amodio et al.
Description
Citation
Citation to related work
Impact Journals, LLC
Has part
Oncotarget
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Embedded videos